Portrait des auf die Bereiche Biologie & Biotechnologie spezialisierten Patentanwalts Dr. Jürgen Meier

Dr. Jürgen Meier

Dipl.-Biol.
PARTNER
Patentanwalt, European Patent Attorney
UPC Representative
meier@vossius.eu

Dr. Jürgen Meier studied biology and biochemistry at the universities of Freiburg im Breisgau, Sussex (England) and Dundee (Scotland). After completion of his Ph.D. at the European Molecular Biology Laboratory (EMBL) in Heidelberg, he worked for several years at the Centre de Recherche en Neuroscience of McGill University in Montréal, Canada. He joined VOSSIUS in 1998 and became European Patent Attorney in 2001. He is also admitted to practice as German Patent Attorney (Patentanwalt) and European Trademark Attorney and is a partner of VOSSIUS since 2004.

Dr. Meier specializes in prosecution proceedings, oppositions, appeals, revocation proceedings as well as infringement proceedings relating to biotechnology, pharmaceuticals and second medical uses. He has extensive experience, inter alia, in the prosecution and litigation of antibody technologies, including important drugs like blinatumomab, trastuzumab or rituximab, in the pharmaceutical area, in particular the neurological and metabolic field, including drugs in Alzheimer or in diabetes intervention, in small molecule drugs, like bisphosphonates or antibiotics. He has also experience in the prosecution and litigation of cases relating to fermentation technologies and microbiology, including amino acid production, alcohol fermentation and brewing technologies.

Further exemplary post and present cases relate to pharmaceutical uses of biologics, antibodies and antibody-drug-conjugates (ADCs), stem cell technologies and their uses, RNA technologies, including miRNA, siRNA diagnostics and therapeutics, SNP diagnostics and biomarkers, microbiological test assays and antigen diagnostics, including M. tuberculosis, Anthrax, HPV, HCV and HIV tests, biomarkers for personalized medicine and companion diagnostics, treatment and dosage regimens, and transgenics and research tools. Also novel sequencing and gene modification technologies (NGTs) are comprised in his portfolio. Novel technologies handled by Dr. Meier also comprise biophysics, laser- and thermophoresis technologies and AI-based subject-matter. Furthermore, he advises national and international clients on employee’s remunerations and employee’s inventions and in portfolio management.

Dr. Meier currently serves as Chairman of the AIPPI Biotech Committee. Furthermore, he gives presentations and lectures on patentability issues of biotechnology, biocomputing inventions as well as formal and legal aspects of patent law. Dr. Meier has published several articles on IP matters. He is editor (together with Oswin Ridderbusch) and author of the book “Antibody Patenting” of the AIPPI Law Series (previous edition and 2nd edition, 2023). Further, he co-authored the book “Second Medical Use Claims” of the AIPPI Law Series (EPO/Chapter; previous editions and 3rd edition, 2025) and the book “From Clones to Claims” (on the case law of the EPO's Technical Boards of Appeal; previous editions and 7th edition, 2023). He also teaches in the "D-course (legal course)" at CEIPI of the Université de Strasbourg, France, at the University of Würzburg, Germany, the Zeppelin University, Friedrichshafen, Germany as well as at the Management Center Innsbruck (MCI), in Austria.

Memberships: Patentanwaltskammer, epi, AIPPI (Chairman of SC Biotechnology and European Member of Biotech working group), FICPI, VPP

Languages: English, German, French

Special Fields 

  • Cell Biology and Microbiology
  • Neurosciences
  • Molecular Biology and Gene therapy
  • Biocomputing
  • Advising on Patent Portfolios, Freedom-to-Operate Analyses
  • Law on Employees’ Inventions
  • Oppositions and Litigations
"He is extremely knowledgeable, responsive and takes a proactive approach to supporting his clientele."
IAM Patent 1000

Practice Group

Biology & Biotechnology

Practice Areas

Patent & Utility Model Prosecution
Opposition & Revocation
Patent & Utility Model Litigation
Employee Inventions
Unitary Patent & UPC
Due Diligence & Freedom-to-Operate Analysis
All Industries

Recognitions

17th Edition (2026)

Practice Areas
Intellectual Property Law
Patent Attorney

Recognized since 2020

Handelsblatt

Deutschlands Beste Anwälte
Empfohlener Anwalt – Gewerblicher Rechtsschutz
Patentrecht

Empfohlen seit 2019

IAM Strategy 300: The World’s Leading IP Strategists

Ranked in Biotech, IP management consultancy, Legal, Licensing, Pharmaceuticals/life sciences, Technology transfer, Valuation

Ranked since 2023

IAM Patent 1000 - Recommended

“Jürgen Meier excels across the board when handling patents related to biotechnology and pharmaceuticals, especially antibodies. He is extremely knowledgeable, responsive and takes a proactive approach to supporting his clientele.”

“Jürgen provides very detailed, in-depth opinions and strategic advice, delivering a work product that is always excellent and exceeds expectations.”

Recommended since 2015

The Legal 500 Germany / EMEA - Recommended Attorney

“The quality of their work results is entirely satisfactory. Hans-Rainer Jaenichen and Jürgen Meier are particularly recommended as very experienced partners.”

“Best biotech team in the market; excellent client communication.”

Patent Prosecution - Recommended in 2019, and 2021 to 2025
Patent Litigation: Patent Lawyers - Recommended since 2023

Lexology Index (formerly Who’s Who Legal WWL)

IP - Patent Agents & Attorneys (Thought Leaders - IP)

IP - Germany - Patent Agents

Germany - Life Sciences

Recognised in 2019 and since 2022

IP STARS from Managing IP (MIP)

Patent Star

Ranked in 2016 and 2019

World Intellectual Property Review (WIPR)

Recommended Attorney

Ranked in 2024

Publications

Book
Antibody Patenting: A Practitioner's Guide to Drafting, Prosecution and Enforcement

Kluwer Law International, 2nd Edition, 2023

 

Fachbuch
Antibody Patenting: A Practitioner's Guide to Drafting, Prosecution and Enforcement

Kluwer Law International, 2. Auflage, 2023

Book
From Clones to Claims

Carl Heymanns Verlag, 7th Edition, 2023